Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary

Authors

John Anderson
James R Gavin
Davida F Kruger, Henry Ford HealthFollow
Eden Miller

Recommended Citation

Anderson J, Gavin J, Kruger D, Miller E. Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary. Clin Diabetes 2022; 40(3):265-269.

Document Type

Article

Publication Date

2022

Publication Title

Clin Diabetes

PubMed ID

35983422

Volume

40

Issue

3

First Page

265

Last Page

269